PIK3CA mutations in breast cancer are associated with poor outcome

S.Y. Li, M. Rong, F. Grieu, Barry Iacopetta

Research output: Contribution to journalArticlepeer-review

161 Citations (Scopus)


The phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway is considered to play an important role in tumorigenesis. Frequent somatic mutations in the PI3K subunit p110 alpha (PIK3CA) occur in a variety of cancer types. We screened 250 primary human breast tumors for mutations in PIK3CA in order to determine associations with pathological features and with patient outcome. The frequency of PIK3CA mutations in the C2, helical and kinase domains was 35% (88/250). Mutations were associated with larger tumor size (p=0.004) and positive estrogen receptor status (p=0.008). Patients with PIK3CA mutations showed significantly worse survival (p=0.004), particularly those with positive estrogen receptor expression or non-amplified erbB2 (both p=0.002). PIK3CA mutation was an independent factor for worse survival in breast cancer patients with non-amplified erbB2 (RR = 2.6, 95% CI [1.2-5.5], p = 0.016).
Original languageEnglish
Pages (from-to)91-95
JournalBreast Cancer Research and Treatment
Issue number1
Publication statusPublished - 2006


Dive into the research topics of 'PIK3CA mutations in breast cancer are associated with poor outcome'. Together they form a unique fingerprint.

Cite this